Figure 4From: Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer Forest plot of event free survival for anastrozole vs. tamoxifen in fixed-effect model in which all 4 trials were included. aFor ATAC trial, HR for recurrence free survival of estrogen receptor positive patients was included in the model. Test for heterogeneity (Q) = 2.244 (P = 0.523). HR: hazard rate, CI: confidence interval.Back to article page